Risuteganib is a drug under investigation, mainly for the treatment of dry age-related macular degeneration (AMD) and diabetic macular edema (DME). It is a synthetic peptide that functions as a integrin inhibitor, targeting specific integrin heterodimers involved in the progression of these blinding eye diseases. By inhibiting these cellular pathways, risuteganib aims to restore retinal homeostasis, improve mitochondrial function, and reduce inflammation. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include Luminate, risuteganibum and ALG1001. Its PubChem CID is 130476723.
Risuteganib
| CAS No | 1307293-62-4 |
|---|---|
| Molecular Formula | C22H39N9O11S |
| Molecular Weight | 637.7 g/mol |
| Synonyms | (2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Risuteganib is a drug under investigation, mainly for the treatment of dry age-related macular degeneration (AMD) and diabetic macular edema (DME). It is a synthetic peptide that functions as a integrin inhibitor, targeting specific integrin heterodimers involved in the progression of these blinding eye diseases.
The listed CAS number is 1307293-62-4.
The listed molecular formula is C22H39N9O11S.
The listed molecular weight is 637.7 g/mol.
(2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid.
The source lists Luminate, risuteganibum and ALG1001.